Abdel-Nabi
et al. Staging of Primary Colorectal Carcinomas with Fluorine-18
Fluorodeoxyglucose Whole-Body
PET: Correlation with Histopathologic and CT findings. Radiology 1998; 206:755-60
Flamen
P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, Peeters
M, Penninckx F, Filez L, Bleichrodt RP, Mortelmans L. Unexplained rising
carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal
cancer. the utility of positron emission tomography (PET). Eur J Cancer
2001 May;37(7):862-9
Valk PE
, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, Greiss
HB, Hofer GA. Whole-body PET imaging with [18F]fluorodeoxyglucose in management
of recurrent colorectal cancer. Arch Surg 1999 May;134(5):503-11
T.J.M. Ruers
, B.S. Langenhoff, N. Neeleman, G.J. Jager, S. Strijk, Th. Wobbes,
F.H.M. Corstens, and W.J.G. Oyen. Value of Positron Emission Tomography
With [F-18]Fluorodeoxyglucose in Patients With Colorectal Liver Metastases:
A Prospective Study. J Clin Oncol 2002; 20:388-395.
Steven M. Strasberg, MD,
Farrokh Dehdashti, MD, Barry A. Siegel, MD, Jeffrey A. Drebin, MD,
and David Linehan, MD. Survival of Patients Evaluated by FDG-PET Before
Hepatic Resection for Metastatic Colorectal Carcinoma: A Prospective Database
Study. ANNALS OF SURGERY 2001;Vol. 233, No. 3, 293–299
Huebner
et al. A meta-analysis of the literature for whole-body FDG PET
detection of recurrent colorectal cancer. J Nucl Med 2000 Jul;41(7):1177-89.
Kalff V,
Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The Clinical Impact
of (18)F-FDG PET in Patients with Suspected or Confirmed Recurrence of
Colorectal Cancer: A Prospective Study. J Nucl Med 2002 Apr;43(4):492-9
